Repurposing Clinical Candidates for Nipah and Hendra Viruses.

Q: What does this research mean for the field?

Existing clinical candidates can be repurposed as antivirals against Nipah and Hendra viruses, providing empirical guidance for prioritizing future antiviral development. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Thomas R. Lane; Olivier Escaffre; Lihong Zhang; Jennifer K Smith; Terry L. Juelich; Alexander N. Freiberg; Sean Ekins

doi:10.1021/acsinfecdis.6c00206

April 29, 2026

Repurposing Clinical Candidates for Nipah and Hendra Viruses.

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to explore the potential of existing antiviral drugs for treating Nipah and Hendra viruses.
Identified clinical candidates with antiviral potential against NiV and HeV.
Conducted in vitro testing to evaluate efficacy of selected compounds.
Several candidates showed promising antiviral activity against NiV and HeV in vitro.
Results guide future prioritization of antiviral development efforts.

Implication

Investigates antiviral repurposing for Nipah and Hendra viruses, suggesting new treatment approaches.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lane et al. (2026) studied this question.

synapsesocial.com/papers/69f444d3967e944ac55678fb https://doi.org/10.1021/acsinfecdis.6c00206

View Full Paper

Ask AI

Bookmark

Share

Repurposing Clinical Candidates for Nipah and Hendra Viruses.

Key Points

Implication

Discussion

Cite This Study

Repurposing Clinical Candidates for Nipah and Hendra Viruses.

Key Points

Implication

Discussion

Cite This Study

Keep reading

Keep reading